Deals this week: Enteris BioPharma, Actelion Pharmaceuticals, Ritter Pharmaceuticals

26th January 2017 (Last Updated January 26th, 2017 18:30)

French pharmaceutical company Sanofi and US-based bio-technology company Enteris BioPharma have reached an agreement to perform a feasibility study to develop an oral formulation of one of the former’s pre-clinical stage peptides with the help of Peptelligence, a patented oral peptide and small molecule delivery platform owned by the latter.

French pharmaceutical company Sanofi and US-based bio-technology company Enteris BioPharma have reached an agreement to perform a feasibility study to develop an oral formulation of one of the former’s pre-clinical stage peptides with the help of Peptelligence, a patented oral peptide and small molecule delivery platform owned by the latter.

The investigational oral therapeutic is meant to treat type 2 diabetes.

Ukraine-based chemical company Enamine and Swiss-based pharmaceutical company Actelion Pharmaceuticals have expanded their early drug discovery agreement that is focused on cardiovascular and central nervous system disorders, immunology, infectious diseases and oncology.

Expansion of the agreement was originally signed in 2005 and enables Enamine to produce exclusive screening compounds by decorating scaffold compounds supplied by Actelion with Enamine’s building blocks.

"US-based Ritter Pharmaceuticals will study the role of the microbiome and RP-G28 in metabolic syndrome with the help of University of Nebraska, under an agreement signed between the two."

US-based Ritter Pharmaceuticals will study the role of the microbiome and RP-G28 in metabolic syndrome with the help of University of Nebraska, under an agreement signed between the two.

The agreement is aimed at the development of microbiome therapeutics in metabolic syndrome.

Tetra Bio-Pharma subsidiary PhytoPain Pharma has signed a clinical research agreement with Sante Cannabis.

The partnership is aimed at the development of late-phase clinical trial protocols needed to evaluate the safety and efficacy of PPP001 so that prescription drug approval could be obtained from regulatory authorities in Canada and the US.